Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of hyperosmolar glucose-added dialysate on dialysis adequacy in end-stage renal disease
IRCT20260721070285N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of glucose in end-stage kidney disease (ESKD) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Dialysis adequacy, Blood glucose and 1 more. Started Oct 2026; status: completed.
02
Drugs
glucose
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20260721070285N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260721070285N1.